メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
Keio University ホーム
ヘルプ＆FAQ
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
齋藤 義正
薬学科
ウェブサイト
https://k-ris.keio.ac.jp/html/100012953_ja.html
h-index
6147
被引用数
40
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
1999 …
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(102)
類似のプロファイル
(6)
フィンガープリント
Yoshimasa Saitoが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Organoid
69%
Hepatocellular Carcinoma
39%
Hepatocyte
29%
Biliary Tract Cancer
29%
Cholangiocarcinoma
29%
microRNA
29%
Neoplasm
27%
Biological Marker
22%
Helicobacter Pylori
21%
Malignant Neoplasm
20%
Cancer Cell Line
19%
Antioxidant
19%
Nonalcoholic Fatty Liver
19%
Personalized Medicine
19%
DNA (Cytosine 5) Methyltransferase 1
19%
Barrett Esophagus
19%
Metaplasia
19%
Pancreas Cancer
18%
Oxidative Stress
17%
Stem Cell
16%
Disease
15%
Gut Microbiota
15%
In Vitro
15%
Gallstone
14%
Hepatobiliary Cancer
13%
Carcinogenesis
13%
Hepatic Progenitor Cell
12%
Reflux
11%
Gemcitabine
11%
Odds Ratio
10%
Symptom
9%
Rescue Therapy
9%
Sitafloxacin
9%
Vorinostat
9%
Protein Expression
9%
Volunteer
9%
Edaravone
9%
microRNA 155
9%
Prevalence
9%
Gut
9%
Vonoprazan
9%
Epigenomics
9%
Cross Sectional Study
9%
Salvage Enzyme
9%
Roxatidine
9%
Drug Prescription
9%
DNA Methyltransferase 3B
9%
Microbial Diversity
9%
Transcription Factor Nrf2
9%
Carcinogenicity
9%
Biochemistry, Genetics and Molecular Biology
MicroRNA
100%
Cancer Cell
75%
Epigenetics
41%
DNA Methylation
36%
DNA Methyltransferase
29%
Epigenetic Therapy
26%
Stem Cell
24%
Tumor Suppressor Protein
22%
Promoter Region
22%
Genetics
19%
Microarrays
15%
Mouse
15%
Cell Proliferation
15%
interferon
14%
Transcription Factors
13%
Stem Cell Marker
12%
Gene Expression
12%
Oncogene
12%
DNA Hypomethylation
11%
Antisense
11%
Histone Modification
11%
Epigenetic Modification
11%
Messenger RNA
10%
Stomach Emptying
9%
Adipocyte
9%
Nucleic Acid
9%
Transcription Factor EZH2
9%
Azacitidine
9%
Epigenetics
9%
NAD(P)H Oxidase
9%
Drug Screening
9%
Astaxanthin
9%
Cell Survival
9%
Gene Mutation
9%
Immune Response
9%
CTCF
9%
Oncogene C Myc
9%
Lipid Storage
9%
Cancer Epigenetics
9%
Mir-126
9%
Actin Capping
9%
Lipid Profile
9%
Immunocompetent Cell
9%
Platelet Count
9%
Hepatitis C Virus
9%
DNMT1
9%
Genotyping
9%
Protein Methylation
9%
BCL6
9%
Otsuka Long Evans Tokushima Fatty Rat
9%
Keyphrases
MicroRNA
25%
Senescence
23%
Triple Therapy
21%
Organoids
21%
Functional Hepatocytes
19%
Helicobacter Pylori Eradication
19%
Biliary Tract Cancer
19%
Human Liver
19%
Epigenetic Silencing
14%
Organoid Culture
14%
Hepatocytes
14%
Visceral Adipose Tissue
13%
Epigenetic Therapy
13%
Human Liver Cancer Cells
13%
Epigenetics
12%
Chromatin Remodeling
12%
DNA Methyltransferase Inhibitor
12%
Histone Deacetylase Inhibitor (HDACi)
12%
Human Cancer
11%
Tumor Suppressor miRNA
11%
Cancer Cells
11%
Histone Modification
11%
Eradication Therapy
11%
Second-line Therapy
10%
Esomeprazole
10%
Liver
10%
MicroRNA-222
9%
Muscle-specific microRNAs
9%
Size Profile
9%
CYP2C19 Polymorphism
9%
Type I Interferon
9%
Intrahepatic Cholangiocarcinoma (iCCA)
9%
Liver Cirrhosis
9%
MicroRNA-221
9%
Esophageal Metaplasia
9%
Induced Differentiation
9%
Reflux Symptoms
9%
Acute Liver Injury
9%
Edaravone
9%
Suberoylanilide Hydroxamic Acid
9%
Drug Analysis
9%
Establishment Limitation
9%
Intestinal Epithelial Organoids
9%
Rifabutin
9%
7-day Triple Therapy
9%
Antitumor Effect
9%
MiR-142-5p
9%
Hepatobiliary Tumours
9%
Specific Antigen
9%
Cholangiocarcinoma Cells
9%
